A Phase 1 interventional study of BR3003(T) and BR3003B(R1) in Diabetes Mellitus, Type 2, sponsored by Boryung Pharmaceutical Co., Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-27.
Sponsored by Boryung Pharmaceutical Co., Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.
Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 88th largest by enrollment, is one of 3 that started in 2022, is one of 6 in phase 1, and was the 113th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 30–70 · Healthy volunteers
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 20+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–75
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–80
By country, each count listing its studies:
Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 19 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 11 · Phase 3 33 · Phase 4 57
First in 2000; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 103 across the 122 interventional studies. Of the 96 that completed or were terminated, 31 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 122 have an industry lead sponsor. The 10 most frequent:
Boryung Pharmaceutical Co., Ltd is the lead sponsor of 143 studies on the registry; 23 are open to participants now.
14 studies in Diabetes Mellitus, Type 2 by Boryung Pharmaceutical Co., Ltd: 3 open now, 3 under way, 1 of them phase 3. Of 11 finished, 0 (0%) have results posted.
Among the 14 studies in Diabetes Mellitus, Type 2 by Boryung Pharmaceutical Co., Ltd, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2022, is one of 10 in phase 1, and was the 2nd registered.
Boryung Pharmaceutical Co., Ltd’s Diabetes Mellitus, Type 2 studies by the year they started, since 2021.
4 of the studies testing pioglitazone in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06989723Seoul National University Bundang HospitalPioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT05305287The University of Texas Health Science Center at San AntonioQuantifying Hepatic Mitochondrial Fluxes in Humans | 2027-03-31 |
| NCT04501406University of FloridaLow-Dose Pioglitazone in Patients With NASH (AIM 2) | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boryung Pharmaceutical Co., Ltd’s 14 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
To perform a comparative evaluation on the pharmacokinetics and the safety after administration of "BR3003" and co-administration of "BR3003B" and "BR3003C" in healthy adults.
A randomized, open-label, single oral dose, two-way crossover study under fasting condition. Target number of subjects: 46 subjects in total.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Those who are applicable to the following conditions in 30 days prior to the first administration:
Female subjects: average alcohol intake > 14 units/week
(1 unit= 50 mL of soju, 30 mL of hard liquor or 250 mL of beer)
Those who apply to the following criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The investigational products will be administered according to the treatment groups assigned to each sequence group in Period 1 and Period 2. \*Sequence A \[Period 1\] Co-administration of BR3003B(R1) and BR3003C(R2) (single dose) - Wash out for 7 days \[Period 2\] Administration of BR3003(T) (single dose)
Drug: BR3003(T) · Drug: BR3003B(R1) · Drug: BR3003C(R2)
The investigational products will be administered according to the treatment groups assigned to each sequence group in Period 1 and Period 2. \*Sequence B \[Period 1\] Administration of BR3003(T) (single dose) - Wash out for 7 days \[Period 2\] Co-administration of BR3003B(R1) and BR3003C(R2) (single dose)
Drug: BR3003(T) · Drug: BR3003B(R1) · Drug: BR3003C(R2)
Test drug (T):"BR3003" Boryung Pharmaceutical Co., Ltd.
Also known as: Dapagliflozin 10mg / Pioglitazone 30mg
Reference drug 1 (R1): "BR3003B" of Celltrion Pharm, Inc.
Also known as: Pioglitazone 30mg
Reference drug 2 (R2): "BR3003C" of AstraZeneca Korea
Also known as: Dapagliflozin 10mg
Pharmacokinetic variables - AUC
Area under the plasma concentration versus time curve(AUCt) of Pioglitazone and Dapagliflozin(Blood samples are collected 22 times for each Period.)
Time frame: Pre-dose(0hour), 0.167hour(10 min), 0.333hour(20 min), 0.5hour(30 minutes), 0.667hour(40min), 1hour, 1.5hour, 2hour, 3hour, 4hour, 5hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour
Pharmacokinetic variables - Cmax
Peak Plasma Concentration(Cmax) of Pioglitazone and Dapagliflozin(Blood samples are collected 22 times for each Period.)
Time frame: Pre-dose(0hour), 0.167hour(10 min), 0.333hour(20 min), 0.5hour(30 minutes), 0.667hour(40min), 1hour, 1.5hour, 2hour, 3hour, 4hour, 5hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour
Pharmacokinetic variables - AUC∞
AUC∞ of Pioglitazone and Dapagliflozin (Blood samples are collected 22 times for each Period.)
Time frame: Pre-dose (0hour), 0.167hour (10min), 0.333hour (20 min), 0.5hour (30 min), 0.667hour (40min), 1hour, 1.5hour, 2hour, 3hour, 4hour, 5hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour
Pharmacokinetic variables - AUCt/AUC∞
AUCt/AUC∞ of Pioglitazone and Dapagliflozin (Blood samples are collected 22 times for each Period.)
Time frame: Pre-dose (0hour), 2hour, 4hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour
Pharmacokinetic variables - Tmax
Tmax of Pioglitazone and Dapagliflozin (Blood samples are collected 22 times for eachour Period.)
Time frame: Pre-dose (0hour), 0.167hour (10min), 0.333hour (20 min), 0.5hour (30 min), 0.667hour (40min), 1hour, 1.5hour, 2hour, 3hour, 4hour, 5hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour
Pharmacokinetic variables - t1/2
t1/2 of Pioglitazone and Dapagliflozin (Blood samples are collected 22 times for eachour Period.)
Time frame: Pre-dose (0hour), 0.167hour (10min), 0.333hour (20 min), 0.5hour (30 min), 0.667hour (40min), 1hour, 1.5hour, 2hour, 3hour, 4hour, 5hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour
Pharmacokinetic variables - AUCt of Pioglitazone M-IV
AUCt of Pioglitazone M-IV (Blood samples are collected 14 times for eachour Period.)
Time frame: Pre-dose (0hour), 2hour, 4hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour
Pharmacokinetic variables - Cmax of Pioglitazone M-IV
Cmax of Pioglitazone M-IV (Blood samples are collected 14 times for eachour Period.)
Time frame: Pre-dose (0hour), 2hour, 4hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour
Pharmacokinetic variables - AUC∞ of Pioglitazone M-IV
AUC∞ of Pioglitazone M-IV (Blood samples are collected 14 times for eachour Period.)
Time frame: Pre-dose (0hour), 2hour, 4hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour
Pharmacokinetic variables - AUCt/AUC∞ of Pioglitazone M-IV
AUCt/AUC∞ of Pioglitazone M-IV (Blood samples are collected 14 times for eachour Period.)
Time frame: Pre-dose (0hour), 2hour, 4hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour
Pharmacokinetic variables - Tmax of Pioglitazone M-IV
Tmax of Pioglitazone M-IV (Blood samples are collected 14 times for eachour Period.)
Time frame: Pre-dose (0hour), 2hour, 4hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour
Pharmacokinetic variables - t1/2 of Pioglitazone M-IV
t1/2 of Pioglitazone M-IV (Blood samples are collected 14 times for eachour Period.)
Time frame: Pre-dose (0hour), 2hour, 4hour, 6hour, 8hour, 10hour, 12hour, 14hour, 16hour, 18hour, 24hour, 48hour, 72hour, 96hour
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2022 to primary completion in Jul 2022, 2 months.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 2 months is below that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pioglitazone · Dapagliflozin
Boryung Pharmaceutical Co., Ltd →